OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Kawai Norisuke
Pfizer R&D Japan G.K.
Shinjuku Bunka Quint Bldg., 3-22-7 Yoyogi, Shibuya-ku, Tokyo
+81-3-5309-7000
clinical-trials@pfizer.com
Clinical Trials Information Desk
Pfizer R&D Japan G.K.
Shinjuku Bunka Quint Bldg., 3-22-7 Yoyogi, Shibuya-ku, Tokyo
+81-3-5309-7000
clinical-trials@pfizer.com
Recruiting
Aug. 12, 2021
Aug. 12, 2021
120
Interventional
single arm study
open(masking not used)
uncontrolled control
single assignment
treatment purpose
Inclusion Criteria:
*Evidence of a personally signed and dated informed consent document and assent document.
*Males and females 2 to less than18 years old and weighing at least 10 kg.
*Having a pathology report that confirms colonic inflammation consistent with UC with a clinical diagnosis of UC for at least 12 weeks prior to baseline, with biopsy report supporting the diagnosis of UC.
*Participants diagnosed with UC at age less than 6 years old, must have had testing and be negative for monogenic disorders associated with very early onset IBD.
*Moderately to severely active UC as defined (via screening colonoscopy) by a Mayo score of at least 6, with a rectal bleeding score of at least 1 and an endoscopic subscore of at least 2.
*Pediatric Ulcerative Colitis Activity Index (PUCAI) score greater or equal to 35 .
*No history of dysplasia or colon cancer.
*No evidence or history of untreated or inadequately treated active or latent infection with Mycobacterium Tuberculosis.
*For participants outside of the United States: have had an inadequate response or been intolerant to at least one prior therapy as listed below or have a medical contraindication to such therapies:
*Oral or intravenous (IV) corticosteroids;
*Azathioprine or 6-mercaptopurine;
*TNF inhibitors or anti integrin therapy.
*For participants in the United States: have had an inadequate response or intolerance to TNF inhibitors.
*Stable doses of the following therapies for UC:
*Oral 5 Aminosalicyclic acids (ASA) or sulfasalazine
*Oral corticosteroids equivalent to prednisone at most 1 mg/kg up to a maximum of 20 mg/day or budesonide up to 9 mg/day.
*evidence of prior varicella zoster virus exposure based on serological testing.
*female participant is eligible if she is not pregnant or breastfeeding, If she is a woman of child bearing potential, she needs to be using a contraceptive method that is highly effective (with a failure rate of <1% per year).
Exclusion Criteria:
*Diagnosis of indeterminate colitis, isolated proctitis, microscopic colitis, infectious colitis, Crohn's disease, or clinical findings suggestive of Crohn's disease.
*History of symptomatic obstructive intestinal strictures or active ostomy, or history of colectomy, extensive small bowel resection ( greater than100 centimetres) or short bowel syndrome, or hospitalization for UC related reason(s) within 4 weeks of baseline visit.
*Any factors or clinical characteristics potentially related to the risk of venous thromboembolism that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
*Participants who have previously received tofacitinib or another Janus Kinase inhibitor.
*Vaccination or exposure to a live or attenuated vaccine within the 6 weeks prior to the first dose of study drug, or who are expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study drug.
*Participants having received azathioprine, 6-mercaptopurine, methotrexate, thioguanine, infliximab, adalimumab, golimumab, interferon, cyclosporine, mycophenolate, tacrolimus, IV or rectally administered corticosteroids, natalizumab, vedolizumab, other antiadhesion molecules, or investigational drugs during the specified time periods prior to baseline whereby they may still have pharmacokinetic and/or pharmacodynamic effect in the body of the participant.
*Previous treatment by leukocyte apheresis including selective lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange within 6 months prior to baseline.
*Treatment by specified prohibited concomitant medications, including moderate to potent CYP3A inducers or inhibitors in the specified time periods prior to the first dose of study drug or are expected to receive any of these medications during the study period.
*Chronic and frequent use of antimotility agents for control of diarrhea (ie, diphenoxylate hydrochloride with atropine sulfate or loperamide).
*History of bowel surgery, including cholecystectomy within 6 months prior to baseline, history of appendectomy within 3 months prior to baseline, or significant trauma or major surgery within 4 weeks of screening visit are excluded.
*Participants with the following laboratory values at screening:
*Hemoglobin level lower than 9.0 g/Dl.
*Absolute white blood cell (WBC) count lower than 3000/mm3.
*Absolute neutrophil count lower than 1200/mm3.
*Absolute lymphocyte count lower than 750/mm3.
*Thrombocytopenia as defined by a platelet count lower than 100,000/mm3.
*Estimated bedside Schwartz Glomerular filtration rate (GFR) lower or equal to 40 mL/min/1.73 m2.
*Total bilirubin, aspartate aminostransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal.
*Positive stool examinations for enteric pathogens, pathogenic ova or parasites, or C. difficile toxin at screening.
*Participants infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses.
*History of more than one episode of HZ, a history of disseminated HZ or disseminated herpes simplex.
*History or current symptoms of any lymphoproliferative disorder (eg, Epstein Barr Virus (EBV) related lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorders, multiple myeloma, or signs and symptoms suggestive of currently lymphatic disease).
*Clinically significant infections currently or within 3 months prior to baseline (eg, those requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections), a history of any infection requiring antimicrobial therapy within 2 weeks of baseline, or a history of any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
*Any malignancies or with a history of malignancies, with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin.
*Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees of the Sponsor, including their family members, directly involved in the conduct of the study.
*Participation in other studies involving investigational drug(s) within 2 months prior to study entry and/or during study participation.
*Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
*Pregnant female participants; breastfeeding female participants; fertile female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and through the telephone follow up visit.
2age old over
17age old under
Both
Ulcerative Colitis
Drug: tofacitinib
Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
Primary Outcome Measures :
1.Remission by central read Mayo score following 44 weeks in the maintenance phase. [ Time Frame: Outcome measured at the end of the 44 weeks of the maintenance phase. ]
Remission is defined by central endoscopy read Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
The primary outcome Mayo score is the summation of 4 subscores as listed below :
*patient reported stool frequency (scored 0 to 3)
*patient reported rectal bleeding (scored 0 to 3)
*central read findings on endoscopy (scored 0 to 3)
*physician's global assessment (scored 0 to 3)
The Mayo score has a scale from 0 to 12 points, with the lower score indicating lower ulcerative colitis (UC) disease activity.
Secondary Outcome Measures :
1.Response by Mayo score [ Time Frame: Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44 ]
Response by Mayo score is defined by a decrease from baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.
2.Remission by Mayo score [ Time Frame: Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44 ]
Remission by Mayo score with local and central endoscopy read (induction Week 8, induction Week 16), and with local endoscopy read only (maintenance week 44).
3.Change from baseline in Mayo score. [ Time Frame: Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44 ]
4.Response measured by Partial Mayo Score [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
Response is defined by a partial Mayo score decrease of 2 points or more from baseline. This score is based on the summation of the following subscores :
*stool frequency (scored 0 to 3)
*rectal bleeding (scored 0 to 3)
*physician global assessment (PGA) (scored 0 to 3)
The partial Mayo score has a scale from 0 to 9, with the lower score indicating lower ulcerative colitis (UC) disease activity.
5.Change from baseline in Partial Mayo score [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
Change in partial Mayo score. This score is the summation of 3 distinct dimensions as listed below :
*stool frequency (scored 0 to 3)
*rectal bleeding (scored 0 to 3)
*physician global assessment (PGA) (scored 0 to 3)
The partial Mayo score has a scale from 0 to 9, with the lower score indicating lower ulcerative colitis (UC) disease activity.
6.Response by PUCAI score [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
The Pediatric Ulcerative Colitis Activity Index (PUCAI) score is the summation of 6 dimensions that are all reported by the investigator. The PUCAI score varies from 0 to 85 points, with the lower score indicating lower ulcerative colitis (UC) disease activity. The 6 dimensions of the PUCAI score are as follows :
*abdominal pain
*rectal bleeding
*stool consistency of most stools
*number of stools per 24 hours
*nocturnal stools
*activity level
Response is defined by a PUCAI score decrease of 20 points or more.
7.Change from baseline in PUCAI score [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
The Pediatric Ulcerative Colitis Activity Index (PUCAI) score is the summation of 6 dimensions that are all reported by the investigator
*abdominal pain
*rectal bleeding
*stool consistency of most stools
*number of stools per 24 hours
*nocturnal stools
*activity level
The PUCAI score varies from 0 to 85 points, with the lower score indicating lower ulcerative colitis (UC) disease activity.
8.Percentage of Participants Achieving Endoscopic Improvement at Week 8, 16, and 44 [ Time Frame: Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44 ]
Endoscopic improvement is defined by Mayo endoscopic sub-score of 0 or 1. The Mayo endoscopic sub-score is used to assess ulcerative colitis activity, and ranges from 0 to 3, and is based on the findings during endoscopy. A lower score is indicative of a lower ulcerative colitis (UC) disease activity.
9.Time to flare [ Time Frame: Outcome measured from 2 to 4 months in the study, through study completion, an average of 3 and a half years ]
10.Change from baseline in fecal calprotectin levels [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
11.Change from baseline in serum high sensitivity C-Reactive Protein (hsCRP) levels [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
12.Corticosteroid free remission by Partial Mayo Score [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
Remission is defined by a partial Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and rectal bleeding subscore of 0.
The subscores of the partial Mayo score are:
*stool frequency (scored 0 to 3)
*rectal bleeding (scored 0 to 3)
*physician global assessment (PGA) (scored 0 to 3)
13.Average plasma concentration of tofacitinib (Cavg) [ Time Frame: Outcome measured at baseline, induction Week 8, induction Week 16, maintenance Week 16, maintenance Week 44 ]
14.Evaluation of taste acceptability of tofacitinib oral solution, and acceptability of film coated tablet by choosing one of 5 choices [ Time Frame: Outcome measured at induction week 2 ]
Taste acceptability will be assessed by asking the participant to select one of 5 choices which most adequately reflects the participant's response to taste. Age appropriate tools (using wording and/or graphic facial expressions) will be used to assess taste acceptability.
15.Peak (maximum) plasma concentration of tofacitinib (Cmax) [ Time Frame: Outcome measured at baseline, induction Week 8, induction Week 16, maintenance Week 16, maintenance Week 44 ]
16.Percentage of Participants Achieving Endoscopic Remission at Week 8, 16, and 44 [ Time Frame: Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44 ]
Endoscopic remission is defined by a Mayo endoscopic subscore of 0, out of a maximum of 3 points.
The Mayo endoscopic sub-score is used to assess ulcerative colitis activity, and ranges from 0 to 3, and is based on the findings during endoscopy. A lower score is indicative of a lower ulcerative colitis (UC) disease activity.
17.Remission by PUCAI score [ Time Frame: Outcome measured through study completion, an average of 3 and a half years ]
The Pediatric Ulcerative Colitis Activity Index (PUCAI) score is the summation of 6 dimensions that are all reported by the investigator. The PUCAI score varies from 0 to 85 points, with the lower score indicating lower ulcerative colitis (UC) disease activity. The 6 dimensions of the PUCAI score are as follows :
*abdominal pain
*rectal bleeding
*stool consistency of most stools
*number of stools per 24 hours
*nocturnal stools
*activity level
Remission is defined by a PUCAI score of less than 10 points.
Pfizer Japan Inc.
Kurume University IRB
67 Asahi-machi Kurume-shi, Fukuoka
+81-942-31-7200
kcrc_jimu@kurume-u.ac.jp
Approval
Dec. 21, 2020
Yes
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
